This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (107)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Report of a Visit by US Scientists

Gary R. Noble, MD; Roger H. Bernier, PhD; Elaine C. Esber, MD; M. Carolyn Hardegree, MD; Alan R. Hinman, MD; David Klein, PhD; Alfred J. Saah, MD

JAMA. 1987;257(10):1351-1356.

Abstract
Since the introduction of acellular pertussis vaccines in Japan late in 1981, more than 20 million doses have been administered, mostly to children 2 years of age and older. Clinical studies indicate that mild local and febrile reactions are less frequent after administration of acellular pertussis vaccines than after whole-cell vaccines. Serious adverse events with sequelae occurred in 2-year-old children at approximately the same low rate during the period 1975 through August 1981, when whole-cell vaccines were used, and during August 1981 through 1984, when acellular vaccines were used exclusively. Five household contact studies have yielded vaccine efficacy estimates ranging from 78% to 92% in children 1 year of age or older. In addition, there has been a continuing decrease in reported pertussis incidence from the epidemic peak in 1979. Additional data on the safety and efficacy of acellular pertussis vaccines administered to infants would be useful in consideration of acellular pertussis vaccine licensure in the United States.

(JAMA 1987;257:1351-1356)

Author Affiliations
From the Office of the Director (Dr Noble) and the Center for Prevention Services (Drs Bernier and Hinman), Centers for Disease Control, Atlanta; the National Center for Drugs and Biologics, Food and Drug Administration (Drs Esber and Hardegree); and the National Institute of Allergy and Infectious Diseases, National Institutes of Health (Drs Klein and Saah), Bethesda, Md.

Footnotes
Reprint requests to Technical Information Services, Center for Prevention Services, Centers for Disease Control, Atlanta, GA 30333.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies
Mattoo and Cherry
Clin. Microbiol. Rev. 2005;18:326-382.
ABSTRACT | FULL TEXT  

Extensive Swelling After Booster Doses of Acellular Pertussis-Tetanus-Diphtheria Vaccines
Rennels et al.
Pediatrics 2000;105:e12-e12.
ABSTRACT | FULL TEXT  

A Controlled Trial of a Two-Component Acellular, a Five-Component Acellular, and a Whole-Cell Pertussis Vaccine
Gustafsson et al.
NEJM 1996;334:349-356.
ABSTRACT | FULL TEXT  

Comparison of a Three-Component Acellular Pertussis Vaccine With a Whole-Cell Pertussis Vaccine in 4- Through 6-Year-Old Children
Annunziato et al.
Arch Pediatr Adolesc Med 1994;148:503-507.
ABSTRACT  

Omission Bias and Pertussis Vaccination
Asch et al.
Med Decis Making 1994;14:118-123.
ABSTRACT  

Immunization Status and Reasons for Immunization Delay Among Children Using Public Health Immunization Clinics
Abbotts and Osborn
Arch Pediatr Adolesc Med 1993;147:965-968.
ABSTRACT  

Simultaneous Administration of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine With Measles-Mumps-Rubella and Oral Poliovirus Vaccines
Rothstein et al.
Arch Pediatr Adolesc Med 1993;147:854-857.
ABSTRACT  

Comparison of the Safety and Immunogenicity of Acellular (BIKEN) and Whole-Cell Pertussis Vaccines in 15- to 20-Month-Old Children
Marcinak et al.
Arch Pediatr Adolesc Med 1993;147:290-294.
ABSTRACT  

Immunogenicity and Reactogenicity of Takeda Acellular Pertussis-Component Diphtheria-Tetanus-Pertussis Vaccine in 2- and 3-Month-Old Children in Japan
Kamiya et al.
Arch Pediatr Adolesc Med 1992;146:1141-1147.
ABSTRACT  

Pertussis Vaccines: Seeking a Better Mousetrap
Shapiro
JAMA 1992;267:2788-2790.
ABSTRACT  

Clinical Reactions and Immunogenicity of the BIKEN Acellular Diphtheria and Tetanus Toxoids and Pertussis Vaccine in 4- Through 6-Year-Old US Children
Bernstein et al.
Arch Pediatr Adolesc Med 1992;146:556-559.
ABSTRACT  

A Comparative Trial of the Reactogenicity and Immunogenicity of Takeda Acellular Pertussis Vaccine Combined With Tetanus and Diphtheria Toxoids: Outcome in 3- to 8-Month-Old Infants, 9- to 23-Month-Old Infants and Children, and 24- to 30-Month-Old Children
Kimura et al.
Arch Pediatr Adolesc Med 1991;145:729-733.
ABSTRACT  

Comparison of Acellular and Whole-Cell Pertussis-Component DTP Vaccines: A Multicenter Double-blind Study in 4- to 6-Year-Old Children
Morgan et al.
Arch Pediatr Adolesc Med 1990;144:41-45.
ABSTRACT  

Efficacy and Immunogenicity of Acellular Pertussis Vaccine by Manufacturer and Patient Age
Aoyama et al.
Arch Pediatr Adolesc Med 1989;143:655-659.
ABSTRACT  

Influence of Parental Knowledge and Opinions on 12-Month Diphtheria, Tetanus, and Pertussis Vaccination Rates
Lewis et al.
Arch Pediatr Adolesc Med 1988;142:283-286.
ABSTRACT  

Type-Specific Efficacy of Acellular Pertussis Vaccine
Aoyama et al.
Arch Pediatr Adolesc Med 1988;142:40-42.
ABSTRACT  

Estimated Effects of a Delay in the Recommended Vaccination Schedule for Diphtheria and Tetanus Toxoids and Pertussis Vaccine
Funkhouser et al.
JAMA 1987;257:1341-1346.
ABSTRACT  

Acellular and Whole-Cell Pertussis Vaccines in Japan: Report of a Visit by US Scientists
Cherry and Mortimer
JAMA 1987;257:1375-1376.
ABSTRACT